AstraZeneca Inc. said today that its antibody-mixture drug, its first protective dose other than vaccines against COVID-19, has achieved its main goals in last-stage trials by helping reduce acute COVID-19 infection or death in patients who do not transfer patients to hospitals, reports Al-Rai daily.
